Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR132 | Q9UNW8 | 12/20 | 0.61 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.61 |
| ▸ | CMKLR2 | P46091 | 1/20 | 0.61 |
| ▸ | CMKLR1 | Q99788 | 1/20 | 0.61 |
| ▸ | ECE1 | P42892 | 1/20 | 0.57 |
| ▸ | CA1 | P00915 | 2/20 | 0.56 |
| ▸ | CA2 | P00918 | 2/20 | 0.56 |
| ▸ | CTSL | P07711 | 1/20 | 0.52 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.51 |
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
| ▸ | CTRC | Q99895 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6860313 | 1.00 | GPR132 (0.61) | GPR132GRIA1CMKLR2CMKLR1ECE1 | |
| SCHEMBL2229201 | 0.91 | GPR132 (0.69) | GPR132CMKLR2CMKLR1ECE1PTPN1 | |
| SCHEMBL30037998 | 0.91 | GPR132 (0.69) | GPR132CMKLR2CMKLR1ECE1PTPN1 | |
| SCHEMBL3497405 | 0.91 | GPR132 (0.69) | GPR132CMKLR2CMKLR1ECE1PTPN1 | |
| SCHEMBL2229647 | 0.86 | LNPEP (0.60) | GPR132GRIA1CMKLR2CMKLR1ECE1 | |
| SCHEMBL1071229 | 0.86 | CA1 (0.60) | GPR132GRIA1CMKLR2CMKLR1ECE1 | |
| SCHEMBL3404637 | 0.85 | CA2 (0.69) | GPR132GRIA1CA1CA2CTSL | |
| SCHEMBL5793343 | 0.85 | CA2 (0.69) | GPR132GRIA1CA1CA2CTSL | |
| SCHEMBL8667639 | 0.85 | CA2 (0.69) | GPR132GRIA1CA1CA2CTSL | |
| SCHEMBL8722398 | 0.84 | GRIA1 (0.56) | GPR132GRIA1CMKLR2CMKLR1ECE1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230355550-A1 | KETAMINE COMPOUNDS AND PROCESSES FOR MAKING AND USING THEM | ALTER DOMUS (US) LLC | 2023-11-09 | — | — | US | disclosed |
| US-11753378-B2 | Ketamine compounds and processes for making and using them | ZEVRA THERAPEUTICS, INC. (US) | 2023-09-12 | — | — | US | disclosed |
| US-20220348544-A1 | KETAMINE COMPOUNDS AND PROCESSES FOR MAKING AND USING THEM | ALTER DOMUS (US) LLC | 2022-11-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11753378-B2 | Ketamine compounds and processes for making and using them | OPRK1, GRIK3, GRIN3B | GPR132 2192/4885GRIA1 681/4885CMKLR2 2627/4885 |
| US-20230355550-A1 | KETAMINE COMPOUNDS AND PROCESSES FOR MAKING AND USING THEM | OPRK1, GRIK3, GRIN3B | GPR132 2192/4885GRIA1 681/4885CMKLR2 2627/4885 |
| US-20220348544-A1 | KETAMINE COMPOUNDS AND PROCESSES FOR MAKING AND USING THEM | OPRK1, GRIK3, GRIN3B | GPR132 2192/4885GRIA1 681/4885CMKLR2 2627/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.